Significant Increased Risk Of Cardiotoxic Events Such As Myocardial Infarction, Stroke, And Cardiovascular Death
In the medical literature, more attention is paid to the cardiovascular safety of Imbruvica (ibrutinib), this time with the focus being on Imbruvica-related hypertension and associated serious side effects such as arrhythmias, myocardial infarction, stroke, heart failure, and cardiovascular death.
The medical journal Blood, from the American Society of Hematology, published this article, "Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation", in early October 2019.
From the Abstract for the Blood medical journal article about Imbruvica we get these details about the development of new or worsened hypertension associated with Imbruvica as well as an increased risk of other cardiac events:
- [Imbruvica (ibrutinib)] is linked with potentially-limiting cardiotoxicity, including emerging reports of profound hypertension. However, the long-term incidence, severity, and impacts of hypertension development during [Imbruvica (ibrutinib)] use are unknown.
- Overall, 78.3% of [Imbruvica (ibrutinib)] users developed new or worsened hypertension [mean systolic BP increase 5.2mmHg (+/- 20.7)] over a median of 30 months. New hypertension developed in 71.6% of [Imbruvica (ibrutinib)] users.... Among those without preceding hypertension, 17.7% developed high-grade (BP > 160/100mmHg) hypertension.
- We also evaluated the relationship of hypertension on [Imbruvica (ibrutinib)] to the development of other major-adverse-cardiovascular-events (MACE), including arrhythmias, myocardial infarction, stroke, heart failure, and cardiovascular death.... In multivariable regression containing known predictors of MACE, new or worsened hypertension was associated with increased MACE [hazard ratio (HR) 2.17, 95%CI 1.08-4.38]. No single-antihypertensive class was associated with prevention or control of [Imbruvica (ibrutinib)]-related hypertension.
Strictly Confidential, No Obligation.
In summary, these medical study findings suggest that: (1) Imbruvica is associated with a substantial increase in the incidence as well as the severity of hypertension; and, (2) Imbruvica-related hypertension development may lead to a greater than 2-time increased risk of subsequent cardiotoxic events.
As such, patients given Imbruvica may develop serious side effects including arrhythmias, myocardial infarction, stroke, heart failure, and cardiovascular death.
Just last week we posted this piece, "Patients Treated With Imbruvica Had Increased Rate Of Fatal Cardiac Events Compared To Conventional Chemotherapy", in which we reported Imbruvica cardiovascular adverse drug reactions often occurred soon after the Imbruvica pills were taken.
We will continue to monitor the drug safety profile of Imbruvica and report significant developments, here.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)